MacroGenics Announces Positive Results From Phase 3 SOPHIA Study Of Margetuximab In Patients With HER2 Positive Metastatic Breast Cancer

Reference #18.4f36b9d0.1560885600.1a5c914a

Source : https://www.nasdaq.com/press-release/macrogenics-to-host-conference-call-and-webcast-to-review-margetuximab-phase-3-sophia-study-20190528-00965

MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab